^
    Back
    Association details:
    Biomarker:PIK3CA K111N
    Cancer:HER2 Positive Breast Cancer
    Drug:gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor, mTORC1 inhibitor, mTORC2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

    Excerpt:
    In vivo, PKI-587 inhibited tumor growth in breast (MDA-MB-361, BT474), colon (HCT116), lung (H1975), and glioma (U87MG) xenograft models. PKI-587 at 25 mg/kg (once weekly) shrank large (∼1,000 mm3) MDA-MB-361 tumors and suppressed tumor regrowth. PKI-587 also had significant efficacy in the BT474 [breast; HER2+, PIK3CA (K111N)] xenograft model…
    DOI:
    10.1158/1078-0432.CCR-10-1694